Quantcast

Latest Venlafaxine Stories

2008-10-17 09:00:06

RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced that it has initiated a Phase II clinical trial for its lead product candidate Tyrima(TM) for the treatment of major depressive disorder (MDD). Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A...

2008-10-15 09:00:48

COLLEGEVILLE, Pa., Oct. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today provided an update on its global strategy for desvenlafaxine for the treatment of major depressive disorder (MDD) in adults. Desvenlafaxine has already been approved for the treatment of MDD in adults in the United States, Australia and Brazil, and applications are currently pending in 22 markets. As part of its global regulatory strategy, and in consultation with the Committee for...

2008-10-09 12:00:39

Osmotica Pharmaceutical Corp. is announcing that Venlafaxine Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, which was approved by the U.S. Food and Drug Administration in May, is now commercially available through its marketing partner, Upstate Pharma, LLC, a subsidiary of UCB, Inc. Shipments of the product to wholesalers and other commercial outlets began September 30, 2008 and promotion of the product will commence later in the month. Forrest Waldon, CEO of Osmotica...

2008-09-26 09:00:40

Adheris, Inc., a leader in patient adherence and education programs, announced today the results of a new study that examined adherence rates among patients on SSRI/SNRI antidepressant therapy. Study results showed that patients new to antidepressant treatment and those who had restarted therapy after a lapse of 6 or more months were twice as likely to discontinue therapy in the first 30 days of treatment versus patients previously dispensed an antidepressant. According to lead author...

68971040a3dc55896c39fbd3fdcb02311
2008-09-23 12:10:00

For some time, antidepressants and other drugs have been used collectively to treat hot flashes and other menopausal symptoms that can accompany breast cancer treatment. However, researchers said on Monday that ancient acupuncture methods work just as well as drugs and their effects tend to outlast drugs. Researchers compared acupuncture, which began in China more than 2,000 years ago, to Wyeth antidepressant Effexor, which is prescribed for hot flashes in breast cancer patients. Dr. Eleanor...

2008-09-11 03:00:08

By Klinger, Gil Merlob, Paul Abstract: Depression is common in women of childbearing age and especially during pregnancy and the postpartum period. Selective serotonin reuptake inhibitors (SSRIs) are increasingly being used to treat depression prior to and throughout pregnancy. Up to 30% of the newborn infants exposed to SSRIs may present with clinical signs during the first days after birth. Neonatal abstinence syndrome (NAS) describes this clinical syndrome resulting from prior prolonged...

2008-07-20 03:00:15

By Raymond, Colette B Wazny, Lori D; Honcharik, Patricia L Depressive disorders occur in up to one-third of patients with chronic kidney disease CKD). First-line pharmacologic treatments include selective serotonin reuptake inhibitors and second generation agents, such as bupropion, mirtazapine, and venlafaxine. Although very little research has been conducted on the use of antidepressants in CKD, health care providers should be aware of renal dose adjustments for these agents, drug...

2008-07-16 18:00:42

MADISON, N.J., July 16 /PRNewswire-FirstCall/ -- Wyeth and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today. Under the terms of the...

2008-07-15 09:01:35

WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from major depressive disorder, is the attribute that most influences psychiatrists' prescribing decisions in the treatment of this disorder. Clinical data and expert opinion show that current and emerging therapies...

2008-07-11 12:01:04

By John Sullivan, The Philadelphia Inquirer Jul. 11--Patients taking a popular type of antidepressant are at greater risk for upper gastrointestinal bleeding, according to a new study which appears in the July issue of Archives of General Psychiatry. The risk increases dramatically when the medications, known as selective serontonin reuptake inhibitors, or SSRIs, are combined with drugs that can harm the stomach, such as non-steroidal anti-inflammatory drugs known as NSAIDs, which...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin